ReviewHepatology communications2019
Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease.
Review in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH.Gut microbes · 2025Pooled it
- The Gut Microbiome and Its Impact on Mood and Decision-Making: A Mechanistic and Therapeutic Review.Nutrients · 2025Review
- Review
- A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease.Biomedicines · 2025Review
- Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.Biomedicines · 2024Review
- Article
- Liposome-Based Silibinin for Mitigating Nonalcoholic Fatty Liver Disease: Dual Effects via Parenteral and Intestinal Routes.ACS pharmacology & translational science · 2023Article
- In Vitro Screening for Probiotic Properties ofNutrients · 2023Article
- Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.Frontiers in microbiology · 2023Article
- Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency.PloS one · 2022Article
- Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis.Therapeutic advances in gastroenterology · 2022Article
- Effects of Zhishi Daozhi Decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet.Frontiers in cellular and infection microbiology · 2022Article
- Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.Biomedicines · 2021Review
- Metabolic drivers of non-alcoholic fatty liver disease.Molecular metabolism · 2021Review
- Systemic Immunoregulatory Consequences of Gut Commensal Translocation.Trends in immunology · 2021Review
- Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease.Cell metabolism · 2021Review
- Oral Pathobiont-Induced Changes in Gut Microbiota Aggravate the Pathology of Nonalcoholic Fatty Liver Disease in Mice.Frontiers in immunology · 2021Article
- Dietary Intervention Reverses Fatty Liver and Altered Gut Microbiota during Early-Life Undernutrition.mSystems · 2020Article
- Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.Cancer medicine · 2020Article
- Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms.Clinical journal of gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The gut microbiome, the multispecies community of microbes that exists in the gastrointestinal tract, encodes several orders of magnitude more functional genes than the human genome. It also plays a pivotal role in human health, in part due to metabolism of environmental, dietary, and host-derived substrates, which produce bioactive metabolites. Perturbations to the composition and associated metabolic output of the gut microbiome have been associated with a number of chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD). Here, we review the rapidly evolving suite of next-generation techniques used for studying gut microbiome composition, functional gene content, and bioactive products and discuss relationships with the pathogenesis of NAFLD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.